Hydatidiform Mole

MONDO:0006248 Pathograph 4 Show in embeddings browser gestational trophoblastic disease pregnancy disorder

Hydatidiform mole is the benign, premalignant end of the gestational trophoblastic disease spectrum: an abnormal pregnancy characterized by hydropic swelling of the chorionic villi and proliferation of villous trophoblast. It arises from aberrant fertilization that produces an imbalance of parental genomes. Complete hydatidiform mole is typically diploid and androgenetic (entirely paternal genome, most often from duplication of a single sperm in an ovum lacking maternal chromosomes), with no fetal tissue and diffuse villous hydrops; partial hydatidiform mole is typically triploid and diandric (two paternal genome complements plus one maternal), with focal villous hydrops and a non-viable fetus. The androgenetic/diandric excess of paternally expressed genes and loss of maternally imprinted CDKN1C/p57 drive trophoblastic hyperplasia. A rare familial biparental form (recurrent complete mole) is caused by biallelic maternal-effect variants in NLRP7 or KHDC3L that disrupt the maternal imprinting machinery despite a normal biparental genome. Hydatidiform mole presents with first- trimester bleeding and markedly elevated hCG, is treated by uterine evacuation, and confers a risk of progression to gestational trophoblastic neoplasia, requiring serial hCG surveillance.

Ask OpenScientist

Ask a research question about Hydatidiform Mole. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

4
Pathophys.
3
Phenotypes
4
Pathograph
2
Genes
2
Medical Actions
3
Subtypes
1
Deep Research
◆

Subtypes

3
Complete Hydatidiform Mole
Complete hydatidiform mole is typically diploid and androgenetic, with the entire genome paternally derived. There is no identifiable fetal or embryonic tissue, and the chorionic villi show diffuse hydropic swelling with circumferential trophoblastic hyperplasia. p57 immunostaining is negative in villous cytotrophoblast and stroma because the maternally expressed CDKN1C allele is absent. It carries the highest risk of progression to gestational trophoblastic neoplasia.
Show evidence (2 references)
PMID:33024305 SUPPORT Human Clinical
"Of 564 successfully immunostained CHMs, 563 (99.8%) were p57-negative"
A large prospective series confirms that complete hydatidiform moles are essentially uniformly p57-negative, reflecting absence of the maternally expressed CDKN1C allele.
PMID:33024305 SUPPORT Human Clinical
"Of 153 genotyped CHMs, 148 (96.7%) were androgenetic"
The same series confirms that complete moles are predominantly androgenetic (paternal-only genome).
Partial Hydatidiform Mole
Partial hydatidiform mole is typically triploid and diandric (two paternal genome complements and one maternal), with focal villous hydrops, scattered trophoblastic hyperplasia, and frequently an abnormal non-viable fetus or fetal tissue. p57 immunostaining is retained because a maternal genome is present. Risk of progression to neoplasia is much lower than for complete mole.
Show evidence (2 references)
PMID:33024305 SUPPORT Human Clinical
"Of 497 genotyped PHMs, 484 (97%) were diandric triploid"
Genotyping confirms that partial hydatidiform moles are predominantly diandric triploid (two paternal genome complements plus one maternal).
PMID:33024305 SUPPORT Human Clinical
"Of 486 successfully immunostained PHMs, 481 (99%) were p57-positive"
Partial moles retain p57 expression because a maternal genome (and thus the maternally expressed CDKN1C allele) is present.
Familial Biparental (Recurrent) Hydatidiform Mole
Familial recurrent hydatidiform mole is a rare autosomal recessive, maternal-effect condition in which affected women have recurrent complete moles despite a normal biparental (diploid) genome. It is caused by biallelic variants in NLRP7 or KHDC3L, which disrupt establishment of maternal genomic imprinting in the oocyte so that the conceptus behaves epigenetically like an androgenetic mole.
Show evidence (1 reference)
PMID:38665615 SUPPORT Human Clinical
"The risk of recurrence is seen to be associated with biallelic maternal mutations in NLRP7, KHDC3 L and PAD16 genes."
Recurrent (familial biparental) hydatidiform mole is associated with biallelic maternal-effect mutations in NLRP7 and KHDC3L.
⚙

Pathophysiology

4
Aberrant Fertilization and Parental Genome Imbalance
Hydatidiform mole originates from abnormal fertilization producing an excess of paternal relative to maternal genome. Complete moles are usually diploid androgenetic, arising when an ovum that has lost or inactivated its nucleus is fertilized and the paternal genome is duplicated (or by dispermy); partial moles are usually triploid diandric, arising when a normal ovum is fertilized by two sperm. This parental genome imbalance is the initiating event of molar pregnancy.
trophoblast cell CL:0000351
Downstream
Loss of Genomic Imprinting and p57 Silencing Paternal-genome excess and absent maternal allele dysregulate imprinted gene dosage, silencing maternally expressed CDKN1C/p57.
Show evidence (2 references)
PMID:29083593 SUPPORT Human Clinical
"Hydatidiform moles are characterized by abnormal fertilization, resulting in villous hydrops and trophoblastic hyperplasia"
Hydatidiform mole originates from abnormal fertilization, the initiating event of molar pregnancy.
PMID:29083593 SUPPORT Human Clinical
"being completely androgenetic in complete hydatidiform moles and diandric triploid in partial hydatidiform moles"
Supports the androgenetic (complete) and diandric triploid (partial) origins reflecting paternal-genome excess.
Loss of Genomic Imprinting and p57 Silencing
The androgenetic/diandric genome imbalance dysregulates parent-of-origin imprinted genes. The maternally expressed, paternally imprinted gene CDKN1C (encoding the cyclin-dependent kinase inhibitor p57KIP2) is silenced when the maternal allele is absent (complete mole) or epigenetically disrupted (familial biparental mole), removing a brake on trophoblast proliferation. Negative p57 immunostaining of villous cytotrophoblast and stroma is the diagnostic hallmark of complete mole.
mononuclear cytotrophoblast cell CL:0000523
genomic imprinting GO:0071514 ⚠ ABNORMAL
Downstream
Trophoblastic Hyperplasia and Villous Hydrops Loss of imprinting-dependent growth control drives excessive trophoblast proliferation and hydropic villous swelling.
Show evidence (2 references)
PMID:29083593 SUPPORT Human Clinical
"fundamental genetic event leading to overall alteration of imprinting gene expression in the molar trophoblast"
Overrepresentation of the paternal genome alters imprinted gene expression in the molar trophoblast, the basis for loss of the maternally expressed CDKN1C/p57.
PMID:33024305 SUPPORT Human Clinical
"Of 564 successfully immunostained CHMs, 563 (99.8%) were p57-negative"
Negative p57 immunostaining in complete moles reflects silencing of the maternally expressed CDKN1C allele.
Trophoblastic Hyperplasia and Villous Hydrops
Disinhibited trophoblast proliferation produces the defining pathology of molar pregnancy: enlarged, edematous (hydropic) chorionic villi with hyperplastic villous trophoblast. Excess syncytiotrophoblast secretes markedly elevated human chorionic gonadotropin (hCG), driving the clinical features (hyperemesis, large-for-dates uterus, theca-lutein cysts, and occasionally hyperthyroidism). This molar tissue constitutes the abnormal "grape-like" placental mass.
trophoblast cell CL:0000351
cell population proliferation GO:0008283 ↑ INCREASED
Downstream
Risk of Gestational Trophoblastic Neoplasia Residual or persistent hyperproliferative trophoblast after evacuation can invade and progress to gestational trophoblastic neoplasia.
Show evidence (1 reference)
PMID:29083593 SUPPORT Human Clinical
"Hydatidiform moles are characterized by abnormal fertilization, resulting in villous hydrops and trophoblastic hyperplasia"
Villous hydrops and trophoblastic hyperplasia are the defining pathological features of molar pregnancy.
Risk of Gestational Trophoblastic Neoplasia
After uterine evacuation, a fraction of molar pregnancies progress to gestational trophoblastic neoplasia (persistent/invasive mole or choriocarcinoma), detected by a plateauing or rising hCG. The risk is substantially higher for complete than partial moles. This malignant sequela is captured in the separate Gestational Trophoblastic Neoplasm entry; here it is the principal downstream complication of molar pregnancy that mandates post-evacuation hCG surveillance.
trophoblast cell CL:0000351
Show evidence (2 references)
PMID:29083593 SUPPORT Human Clinical
"Posttreatment, regular β-hCG monitoring is essential to detect potential progression to gestational trophoblastic neoplasia (GTN)."
Post-evacuation hCG surveillance is required precisely because molar pregnancy can progress to gestational trophoblastic neoplasia.
PMID:20673583 SUPPORT Human Clinical
"the premalignant disorders of complete and partial hydatidiform mole, and the malignant disorders of invasive mole"
Complete and partial hydatidiform mole are premalignant precursors of the malignant trophoblastic disorders (gestational trophoblastic neoplasia).
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Hydatidiform Mole Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

3
Digestive 1
Severe nausea and vomiting Nausea and vomiting HP:0002017
Show evidence (1 reference)
PMID:29083593 SUPPORT Human Clinical
"Complete molar pregnancies present with symptoms such as first-trimester vaginal bleeding, severe nausea, and high β-human chorionic gonadotropin (β-hCG) levels."
Severe nausea is listed among the cardinal presenting symptoms of complete hydatidiform mole.
Other 2
Vaginal bleeding Abnormal vaginal bleeding HP:0034263
Show evidence (1 reference)
PMID:29083593 SUPPORT Human Clinical
"Complete molar pregnancies present with symptoms such as first-trimester vaginal bleeding, severe nausea, and high β-human chorionic gonadotropin (β-hCG) levels."
First-trimester vaginal bleeding is a cardinal presenting symptom of complete hydatidiform mole.
Elevated hCG Elevated circulating beta chorionic gonadotropin concentration HP:6000485
Show evidence (1 reference)
PMID:29083593 SUPPORT Human Clinical
"Complete molar pregnancies present with symptoms such as first-trimester vaginal bleeding, severe nausea, and high β-human chorionic gonadotropin (β-hCG) levels."
High beta-hCG levels are a hallmark presenting feature of complete hydatidiform mole.
🧬

Genetic Associations

2
NLRP7
Gene: NLRP7 hgnc:22947
Autosomal recessive
Show evidence (1 reference)
PMID:38665615 SUPPORT Human Clinical
"compound heterozygous for pathogenic variants in the NLRP7 gene"
Biallelic (compound heterozygous) maternal NLRP7 variants cause recurrent molar pregnancy (familial biparental hydatidiform mole).
KHDC3L
Gene: KHDC3L hgnc:33699
Autosomal recessive
Show evidence (1 reference)
PMID:32210488 SUPPORT Human Clinical
"Three maternal-effect genes, including NLRP7, KHDC3L, and PADI6 have been identified as the cause of RHMs."
KHDC3L is one of the maternal-effect genes whose biallelic variants cause recurrent (familial biparental) hydatidiform mole.
💊

Medical Actions

2
Uterine Evacuation
Action: Surgical Procedure NCIT:C15329
Suction dilation and curettage to evacuate the molar pregnancy is the primary treatment for hydatidiform mole.
Show evidence (1 reference)
PMID:29083593 SUPPORT Human Clinical
"Treatment typically involves dilation and curettage (D&C)"
Dilation and curettage (uterine evacuation) is the primary treatment for hydatidiform mole.
Hysterectomy
Action: Hysterectomy Ontology label: Surgical Procedure NCIT:C15329
Hysterectomy is an alternative to uterine evacuation for patients who do not desire future fertility, removing the molar tissue and reducing subsequent gestational trophoblastic neoplasia risk.
Show evidence (1 reference)
PMID:29083593 SUPPORT Human Clinical
"hysterectomy may be considered for patients not desiring future pregnancies"
Hysterectomy is an accepted alternative treatment for molar pregnancy in patients not desiring future fertility.
{ }

Source YAML

click to show 
name: Hydatidiform Mole
creation_date: "2026-06-17T00:00:00Z"
description: >-
  Hydatidiform mole is the benign, premalignant end of the gestational
  trophoblastic disease spectrum: an abnormal pregnancy characterized by
  hydropic swelling of the chorionic villi and proliferation of villous
  trophoblast. It arises from aberrant fertilization that produces an
  imbalance of parental genomes. Complete hydatidiform mole is typically
  diploid and androgenetic (entirely paternal genome, most often from
  duplication of a single sperm in an ovum lacking maternal chromosomes),
  with no fetal tissue and diffuse villous hydrops; partial hydatidiform
  mole is typically triploid and diandric (two paternal genome
  complements plus one maternal), with focal villous hydrops and a
  non-viable fetus. The androgenetic/diandric excess of paternally
  expressed genes and loss of maternally imprinted CDKN1C/p57 drive
  trophoblastic hyperplasia. A rare familial biparental form (recurrent
  complete mole) is caused by biallelic maternal-effect variants in NLRP7
  or KHDC3L that disrupt the maternal imprinting machinery despite a
  normal biparental genome. Hydatidiform mole presents with first-
  trimester bleeding and markedly elevated hCG, is treated by uterine
  evacuation, and confers a risk of progression to gestational
  trophoblastic neoplasia, requiring serial hCG surveillance.
categories:
- Pregnancy Disorder
- Gestational Trophoblastic Disease
disease_term:
  preferred_term: Hydatidiform Mole
  term:
    id: MONDO:0006248
    label: hydatidiform mole
parents:
- gestational trophoblastic disease
- pregnancy disorder
has_subtypes:
- name: Complete Mole
  display_name: Complete Hydatidiform Mole
  description: >-
    Complete hydatidiform mole is typically diploid and androgenetic, with
    the entire genome paternally derived. There is no identifiable fetal or
    embryonic tissue, and the chorionic villi show diffuse hydropic swelling
    with circumferential trophoblastic hyperplasia. p57 immunostaining is
    negative in villous cytotrophoblast and stroma because the maternally
    expressed CDKN1C allele is absent. It carries the highest risk of
    progression to gestational trophoblastic neoplasia.
  evidence:
  - reference: PMID:33024305
    reference_title: "Refined diagnosis of hydatidiform moles with p57 immunohistochemistry and molecular genotyping: updated analysis of a prospective series of 2217 cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of 564 \nsuccessfully immunostained CHMs, 563 (99.8%) were p57-negative"
    explanation: >-
      A large prospective series confirms that complete hydatidiform moles are
      essentially uniformly p57-negative, reflecting absence of the maternally
      expressed CDKN1C allele.
  - reference: PMID:33024305
    reference_title: "Refined diagnosis of hydatidiform moles with p57 immunohistochemistry and molecular genotyping: updated analysis of a prospective series of 2217 cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of 153 genotyped \nCHMs, 148 (96.7%) were androgenetic"
    explanation: >-
      The same series confirms that complete moles are predominantly
      androgenetic (paternal-only genome).
- name: Partial Mole
  display_name: Partial Hydatidiform Mole
  description: >-
    Partial hydatidiform mole is typically triploid and diandric (two
    paternal genome complements and one maternal), with focal villous
    hydrops, scattered trophoblastic hyperplasia, and frequently an abnormal
    non-viable fetus or fetal tissue. p57 immunostaining is retained because
    a maternal genome is present. Risk of progression to neoplasia is much
    lower than for complete mole.
  evidence:
  - reference: PMID:33024305
    reference_title: "Refined diagnosis of hydatidiform moles with p57 immunohistochemistry and molecular genotyping: updated analysis of a prospective series of 2217 cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of 497 genotyped PHMs, 484 (97%) \nwere diandric triploid"
    explanation: >-
      Genotyping confirms that partial hydatidiform moles are predominantly
      diandric triploid (two paternal genome complements plus one maternal).
  - reference: PMID:33024305
    reference_title: "Refined diagnosis of hydatidiform moles with p57 immunohistochemistry and molecular genotyping: updated analysis of a prospective series of 2217 cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of 486 successfully \nimmunostained PHMs, 481 (99%) were p57-positive"
    explanation: >-
      Partial moles retain p57 expression because a maternal genome (and thus
      the maternally expressed CDKN1C allele) is present.
- name: Familial Biparental Mole
  display_name: Familial Biparental (Recurrent) Hydatidiform Mole
  description: >-
    Familial recurrent hydatidiform mole is a rare autosomal recessive,
    maternal-effect condition in which affected women have recurrent complete
    moles despite a normal biparental (diploid) genome. It is caused by
    biallelic variants in NLRP7 or KHDC3L, which disrupt establishment of
    maternal genomic imprinting in the oocyte so that the conceptus behaves
    epigenetically like an androgenetic mole.
  evidence:
  - reference: PMID:38665615
    reference_title: "Decoding the Genetics of Recurrent Molar Pregnancy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The risk of recurrence \nis seen to be associated with biallelic maternal mutations in NLRP7, KHDC3 L and \nPAD16 genes."
    explanation: >-
      Recurrent (familial biparental) hydatidiform mole is associated with
      biallelic maternal-effect mutations in NLRP7 and KHDC3L.
pathophysiology:
- name: Aberrant Fertilization and Parental Genome Imbalance
  description: >-
    Hydatidiform mole originates from abnormal fertilization producing an
    excess of paternal relative to maternal genome. Complete moles are
    usually diploid androgenetic, arising when an ovum that has lost or
    inactivated its nucleus is fertilized and the paternal genome is
    duplicated (or by dispermy); partial moles are usually triploid diandric,
    arising when a normal ovum is fertilized by two sperm. This parental
    genome imbalance is the initiating event of molar pregnancy.
  cell_types:
  - preferred_term: trophoblast cell
    term:
      id: CL:0000351
      label: trophoblast cell
  evidence:
  - reference: PMID:29083593
    reference_title: "Hydatidiform Mole."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hydatidiform moles are \ncharacterized by abnormal fertilization, resulting in villous hydrops and \ntrophoblastic hyperplasia"
    explanation: >-
      Hydatidiform mole originates from abnormal fertilization, the initiating
      event of molar pregnancy.
  - reference: PMID:29083593
    reference_title: "Hydatidiform Mole."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "being completely androgenetic in complete \nhydatidiform moles and diandric triploid in partial hydatidiform moles"
    explanation: >-
      Supports the androgenetic (complete) and diandric triploid (partial)
      origins reflecting paternal-genome excess.
  downstream:
  - target: Loss of Genomic Imprinting and p57 Silencing
    description: >-
      Paternal-genome excess and absent maternal allele dysregulate imprinted
      gene dosage, silencing maternally expressed CDKN1C/p57.
- name: Loss of Genomic Imprinting and p57 Silencing
  description: >-
    The androgenetic/diandric genome imbalance dysregulates parent-of-origin
    imprinted genes. The maternally expressed, paternally imprinted gene
    CDKN1C (encoding the cyclin-dependent kinase inhibitor p57KIP2) is
    silenced when the maternal allele is absent (complete mole) or
    epigenetically disrupted (familial biparental mole), removing a brake on
    trophoblast proliferation. Negative p57 immunostaining of villous
    cytotrophoblast and stroma is the diagnostic hallmark of complete mole.
  cell_types:
  - preferred_term: mononuclear cytotrophoblast cell
    term:
      id: CL:0000523
      label: mononuclear cytotrophoblast cell
  biological_processes:
  - preferred_term: genomic imprinting
    modifier: ABNORMAL
    term:
      id: GO:0071514
      label: genomic imprinting
  evidence:
  - reference: PMID:29083593
    reference_title: "Hydatidiform Mole."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "fundamental genetic event leading to overall alteration of imprinting gene \nexpression in the molar trophoblast"
    explanation: >-
      Overrepresentation of the paternal genome alters imprinted gene
      expression in the molar trophoblast, the basis for loss of the
      maternally expressed CDKN1C/p57.
  - reference: PMID:33024305
    reference_title: "Refined diagnosis of hydatidiform moles with p57 immunohistochemistry and molecular genotyping: updated analysis of a prospective series of 2217 cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Of 564 \nsuccessfully immunostained CHMs, 563 (99.8%) were p57-negative"
    explanation: >-
      Negative p57 immunostaining in complete moles reflects silencing of the
      maternally expressed CDKN1C allele.
  downstream:
  - target: Trophoblastic Hyperplasia and Villous Hydrops
    description: >-
      Loss of imprinting-dependent growth control drives excessive
      trophoblast proliferation and hydropic villous swelling.
- name: Trophoblastic Hyperplasia and Villous Hydrops
  description: >-
    Disinhibited trophoblast proliferation produces the defining pathology of
    molar pregnancy: enlarged, edematous (hydropic) chorionic villi with
    hyperplastic villous trophoblast. Excess syncytiotrophoblast secretes
    markedly elevated human chorionic gonadotropin (hCG), driving the
    clinical features (hyperemesis, large-for-dates uterus, theca-lutein
    cysts, and occasionally hyperthyroidism). This molar tissue constitutes
    the abnormal "grape-like" placental mass.
  cell_types:
  - preferred_term: trophoblast cell
    term:
      id: CL:0000351
      label: trophoblast cell
  biological_processes:
  - preferred_term: cell population proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
  evidence:
  - reference: PMID:29083593
    reference_title: "Hydatidiform Mole."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hydatidiform moles are \ncharacterized by abnormal fertilization, resulting in villous hydrops and \ntrophoblastic hyperplasia"
    explanation: >-
      Villous hydrops and trophoblastic hyperplasia are the defining
      pathological features of molar pregnancy.
  downstream:
  - target: Risk of Gestational Trophoblastic Neoplasia
    description: >-
      Residual or persistent hyperproliferative trophoblast after evacuation
      can invade and progress to gestational trophoblastic neoplasia.
- name: Risk of Gestational Trophoblastic Neoplasia
  description: >-
    After uterine evacuation, a fraction of molar pregnancies progress to
    gestational trophoblastic neoplasia (persistent/invasive mole or
    choriocarcinoma), detected by a plateauing or rising hCG. The risk is
    substantially higher for complete than partial moles. This malignant
    sequela is captured in the separate Gestational Trophoblastic Neoplasm
    entry; here it is the principal downstream complication of molar
    pregnancy that mandates post-evacuation hCG surveillance.
  cell_types:
  - preferred_term: trophoblast cell
    term:
      id: CL:0000351
      label: trophoblast cell
  evidence:
  - reference: PMID:29083593
    reference_title: "Hydatidiform Mole."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Posttreatment, regular \nβ-hCG monitoring is essential to detect potential progression to gestational \ntrophoblastic neoplasia (GTN)."
    explanation: >-
      Post-evacuation hCG surveillance is required precisely because molar
      pregnancy can progress to gestational trophoblastic neoplasia.
  - reference: PMID:20673583
    reference_title: "Gestational trophoblastic disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the premalignant disorders of complete and partial \nhydatidiform mole, and the malignant disorders of invasive mole"
    explanation: >-
      Complete and partial hydatidiform mole are premalignant precursors of
      the malignant trophoblastic disorders (gestational trophoblastic
      neoplasia).
phenotypes:
- name: Vaginal bleeding
  description: >-
    First-trimester vaginal bleeding is the most common presenting symptom of
    hydatidiform mole.
  phenotype_term:
    preferred_term: Abnormal vaginal bleeding
    term:
      id: HP:0034263
      label: Abnormal vaginal bleeding
  evidence:
  - reference: PMID:29083593
    reference_title: "Hydatidiform Mole."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Complete molar pregnancies \npresent with symptoms such as first-trimester vaginal bleeding, severe nausea, \nand high β-human chorionic gonadotropin (β-hCG) levels."
    explanation: >-
      First-trimester vaginal bleeding is a cardinal presenting symptom of
      complete hydatidiform mole.
- name: Elevated hCG
  description: >-
    Markedly elevated serum human chorionic gonadotropin, often far above
    that expected for gestational age, especially in complete mole.
  phenotype_term:
    preferred_term: Elevated circulating beta chorionic gonadotropin concentration
    term:
      id: HP:6000485
      label: Elevated circulating beta chorionic gonadotropin concentration
  evidence:
  - reference: PMID:29083593
    reference_title: "Hydatidiform Mole."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Complete molar pregnancies \npresent with symptoms such as first-trimester vaginal bleeding, severe nausea, \nand high β-human chorionic gonadotropin (β-hCG) levels."
    explanation: >-
      High beta-hCG levels are a hallmark presenting feature of complete
      hydatidiform mole.
- name: Severe nausea and vomiting
  description: >-
    Exaggerated nausea/vomiting (hyperemesis), driven by markedly elevated
    beta-hCG, is a common presenting symptom of complete molar pregnancy.
  phenotype_term:
    preferred_term: Severe nausea and vomiting
    term:
      id: HP:0002017
      label: Nausea and vomiting
  evidence:
  - reference: PMID:29083593
    reference_title: "Hydatidiform Mole."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Complete molar pregnancies \npresent with symptoms such as first-trimester vaginal bleeding, severe nausea, \nand high β-human chorionic gonadotropin (β-hCG) levels."
    explanation: >-
      Severe nausea is listed among the cardinal presenting symptoms of complete
      hydatidiform mole.
genetic:
- name: NLRP7
  gene_term:
    preferred_term: NLRP7
    term:
      id: hgnc:22947
      label: NLRP7
  subtype: Familial Biparental Mole
  inheritance:
  - name: Autosomal recessive
    inheritance_term:
      preferred_term: Autosomal recessive inheritance
      term:
        id: HP:0000007
        label: Autosomal recessive inheritance
    evidence:
    - reference: PMID:38665615
      reference_title: "Decoding the Genetics of Recurrent Molar Pregnancy."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The risk of recurrence \nis seen to be associated with biallelic maternal mutations in NLRP7, KHDC3 L and \nPAD16 genes."
      explanation: >-
        Recurrence is associated with biallelic maternal mutations,
        consistent with autosomal recessive (maternal-effect) inheritance.
  evidence:
  - reference: PMID:38665615
    reference_title: "Decoding the Genetics of Recurrent Molar Pregnancy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "compound heterozygous for pathogenic variants in the NLRP7 gene"
    explanation: >-
      Biallelic (compound heterozygous) maternal NLRP7 variants cause
      recurrent molar pregnancy (familial biparental hydatidiform mole).
- name: KHDC3L
  gene_term:
    preferred_term: KHDC3L
    term:
      id: hgnc:33699
      label: KHDC3L
  subtype: Familial Biparental Mole
  inheritance:
  - name: Autosomal recessive
    inheritance_term:
      preferred_term: Autosomal recessive inheritance
      term:
        id: HP:0000007
        label: Autosomal recessive inheritance
    evidence:
    - reference: PMID:32210488
      reference_title: "Founder Effect of KHDC3L, p.M1V Mutation, on Iranian Patients with Recurrent Hydatidiform Moles."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "is also the first report of the \nhomozygous state that has led to RHM."
      explanation: >-
        A homozygous KHDC3L variant causing recurrent hydatidiform mole is
        consistent with autosomal recessive inheritance.
  evidence:
  - reference: PMID:32210488
    reference_title: "Founder Effect of KHDC3L, p.M1V Mutation, on Iranian Patients with Recurrent Hydatidiform Moles."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Three \nmaternal-effect genes, including NLRP7, KHDC3L, and PADI6 have been identified \nas the cause of RHMs."
    explanation: >-
      KHDC3L is one of the maternal-effect genes whose biallelic variants
      cause recurrent (familial biparental) hydatidiform mole.
treatments:
- name: Uterine Evacuation
  description: >-
    Suction dilation and curettage to evacuate the molar pregnancy is the
    primary treatment for hydatidiform mole.
  treatment_term:
    preferred_term: Surgical Procedure
    term:
      id: NCIT:C15329
      label: Surgical Procedure
  evidence:
  - reference: PMID:29083593
    reference_title: "Hydatidiform Mole."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Treatment \ntypically involves dilation and curettage (D&C)"
    explanation: >-
      Dilation and curettage (uterine evacuation) is the primary treatment
      for hydatidiform mole.
- name: Hysterectomy
  description: >-
    Hysterectomy is an alternative to uterine evacuation for patients who do not
    desire future fertility, removing the molar tissue and reducing subsequent
    gestational trophoblastic neoplasia risk.
  treatment_term:
    preferred_term: Hysterectomy
    term:
      id: NCIT:C15329
      label: Surgical Procedure
  evidence:
  - reference: PMID:29083593
    reference_title: "Hydatidiform Mole."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "hysterectomy may be \nconsidered for patients not desiring future pregnancies"
    explanation: >-
      Hysterectomy is an accepted alternative treatment for molar pregnancy in
      patients not desiring future fertility.
📚

References & Deep Research

Deep Research

1
Falcon ▸
1. Disease Information
Edison Scientific Literature 26 citations 2026-06-17T12:49:56.250892

1. Disease Information

1.1 Definition and current understanding

Hydatidiform mole is an abnormal gestation characterized by hydropic swelling of chorionic villi with trophoblastic hyperplasia, and is classified into complete hydatidiform mole (CHM) and partial hydatidiform mole (PHM) based on genetic constitution and associated morphology (senat2024gestationaltrophoblasticdisease pages 4-7, gonzalez2024gestationaltrophoblasticdisease pages 2-4).

  • CHM (classic concept): androgenetic diploidy with paternal-only genome, typically 46,XX, usually no fetal tissue (gonzalez2024gestationaltrophoblasticdisease pages 1-2, senat2024gestationaltrophoblasticdisease pages 4-7).
  • PHM (classic concept): diandric triploidy with maternal+paternal contribution, commonly 69,XXY (also 69,XXX/69,XYY reported), often with fetal tissue (gonzalez2024gestationaltrophoblasticdisease pages 2-4, senat2024gestationaltrophoblasticdisease pages 4-7).

1.2 Common synonyms / alternative names

  • “Molar pregnancy”
  • “Complete mole” / “Partial mole”
  • Included under GTD; post-evacuation malignant/persistent disease is often described as post-molar gestational trophoblastic neoplasia (post-molar GTN) (larsson2025treatmentoutcomesand pages 1-2, joyce2024evaluationofbiomarkers pages 62-66).

1.3 Key identifiers (available in retrieved evidence)

  • ICD-10 (reported in a Swedish population-based GTN study methods/coding): non-specified hydatidiform mole O01.9; GTN-related codes reported include invasive mole D39.2A, PSTT D39.2C, choriocarcinoma C58.9, and ETT morphology codes (91043/91053/m91053) (larsson2025treatmentoutcomesand pages 1-2).
  • FIGO/WHO classification references: WHO 2020 classification for GTD is explicitly cited in a 2024 biomarker thesis-like document; FIGO diagnostic criteria for post-molar GTN are also summarized (joyce2024evaluationofbiomarkers pages 62-66, larsson2025treatmentoutcomesand pages 1-2).
  • OMIM (recurrent/familial forms): NLRP7-associated recurrent HM labeled HYDM1 (OMIM#231090); KHDC3L-associated labeled HYDM2 (OMIM#614293) (kocabey2023highriskof pages 1-2).

Not found in retrieved full-text set: MeSH descriptor ID, Orphanet ID, MONDO ID.

1.4 Evidence provenance

This report is derived from aggregated disease-level resources (reviews/systematic reviews) and human clinical/registry/cohort studies and case series (senat2024gestationaltrophoblasticdisease pages 4-7, gonzalez2024gestationaltrophoblasticdisease pages 2-4, larsson2025treatmentoutcomesand pages 1-2, zhu2025demographicsriskfactors pages 1-2, kocabey2023highriskof pages 1-2).

2. Etiology

2.1 Primary causal mechanisms

Abnormal fertilization leading to abnormal genomic dosage and imprinting is the core etiologic theme.

  • Sporadic CHM: typically arises when an “empty” ovum (lacking maternal genome) is fertilized by one sperm with duplication or by two sperm, producing androgenetic diploidy (usually 46,XX) (gonzalez2024gestationaltrophoblasticdisease pages 1-2).
  • Sporadic PHM: typically results from dispermy (two sperm) fertilizing a normal ovum, producing diandric triploidy (commonly 69,XXY) (gonzalez2024gestationaltrophoblasticdisease pages 1-2, gonzalez2024gestationaltrophoblasticdisease pages 2-4).

2.2 Risk factors (human clinical/epidemiology)

Consistently reported clinical risk factors include: - Maternal age extremes: increased under ~20 and over 40 years (senat2024gestationaltrophoblasticdisease pages 4-7). A review reports ~2.5-fold increased risk >35 and fivefold >40 (gonzalez2024gestationaltrophoblasticdisease pages 1-2). A cohort review lists maternal age >40 among established risk factors for post-molar GTN (zhu2025demographicsriskfactors pages 1-2). - Prior molar pregnancy: prior HM increases future HM risk; one review cites ~1–2% increased future HM risk and higher risk with multiple prior moles (florea2023hydatidiformmole—betweenchromosomal pages 8-9). - High pre-evacuation hCG and large uterine/lesion metrics: pre-evacuation β-hCG >100,000 mIU/mL, uterine size larger than gestational age, and large theca lutein cysts are repeatedly noted predictors of post-molar GTN (florea2023hydatidiformmole—betweenchromosomal pages 9-11, zhu2025demographicsriskfactors pages 1-2).

2.3 Protective factors

Protective factors were not explicitly identified in the retrieved evidence corpus.

2.4 Gene–environment interactions

Not explicitly described in the retrieved evidence corpus.

3. Phenotypes

3.1 Core clinical phenotypes (typical onset: early pregnancy/first trimester)

Common clinical presentation includes: - Vaginal bleeding (often first trimester) (joyce2024evaluationofbiomarkers pages 62-66, senat2024gestationaltrophoblasticdisease pages 4-7, riccio2023recurrenthydatidiformmoles pages 1-2) - Hyperemesis / severe nausea-vomiting (senat2024gestationaltrophoblasticdisease pages 4-7, gonzalez2024gestationaltrophoblasticdisease pages 2-4, riccio2023recurrenthydatidiformmoles pages 1-2) - Uterine size larger than expected (senat2024gestationaltrophoblasticdisease pages 4-7) - Pelvic pressure/pain (gonzalez2024gestationaltrophoblasticdisease pages 2-4) - Theca lutein ovarian cysts; frequency reported ~9–25% (senat2024gestationaltrophoblasticdisease pages 4-7) - Pregnancy-induced hypertension / early preeclampsia (senat2024gestationaltrophoblasticdisease pages 4-7, riccio2023recurrenthydatidiformmoles pages 1-2) - Hyperthyroidism/thyrotoxicosis due to high β-hCG “molecular mimicry” with TSH (gonzalez2024gestationaltrophoblasticdisease pages 2-4, riccio2023recurrenthydatidiformmoles pages 1-2)

A 2024 biomarker-focused document notes that earlier detection has reduced severe presentations such as anemia, hyperemesis, preeclampsia, and hyperthyroidism (joyce2024evaluationofbiomarkers pages 62-66).

3.2 Laboratory abnormalities

  • Markedly elevated β-hCG; CHM often has very high hCG and may exceed 100,000 U/L (joyce2024evaluationofbiomarkers pages 62-66, senat2024gestationaltrophoblasticdisease pages 4-7).

3.3 Imaging phenotypes

  • Ultrasound “snowstorm/blizzard” appearance and “grape-like” vesicular/cystic changes are classic for CHM and may be identified around 8–10 weeks gestation in some settings (senat2024gestationaltrophoblasticdisease pages 4-7, gonzalez2024gestationaltrophoblasticdisease pages 2-4, riccio2023recurrenthydatidiformmoles pages 1-2).
  • In one 2024 source, ultrasound detection was higher for CHM (88%) than PHM (56%) (joyce2024evaluationofbiomarkers pages 62-66).

3.4 Pathology / histopathology phenotypes

CHM classically shows edematous hydropic villi with circumferential trophoblastic hyperplasia; PHM shows mixed villous populations (large hydropic and smaller fibrotic villi) (gonzalez2024gestationaltrophoblasticdisease pages 2-4).

3.5 Suggested ontology terms (examples)

HPO (phenotypes): - Abnormal uterine bleeding; Hyperemesis gravidarum; Pelvic pain; Enlarged uterus; Ovarian cyst; Hypertension in pregnancy / Preeclampsia; Hyperthyroidism; Elevated chorionic gonadotropin.

LOINC (lab concepts, examples): - “Chorionic gonadotropin.beta [Units/volume] in Serum or Plasma”.

UBERON (anatomy): uterus, placenta/chorionic villi, ovary.

(Exact ontology IDs should be assigned during curation in the target system; not all IDs were present in the retrieved sources.)

4. Genetic / Molecular Information

4.1 Core genetic concepts (sporadic CHM vs PHM)

  • CHM: androgenetic diploidy (paternal-only genome), usually 46,XX (gonzalez2024gestationaltrophoblasticdisease pages 1-2).
  • PHM: diandric triploidy, commonly 69,XXY (gonzalez2024gestationaltrophoblasticdisease pages 2-4).

4.2 Recurrent/biparental hydatidiform mole (maternal-effect gene etiologies)

A major advance is recognition of autosomal recessive maternal-effect causes of recurrent HM, in which conceptions may be diploid biparental but still manifest a complete-mole phenotype due to imprinting failure.

  • In a large cohort of 113 recurrent HM patients, authors report that 50–80% carry biallelic pathogenic variants in NLRP7 or KHDC3L, and all molar tissues from these patients were diploid biparental; mutation-negative patients showed heterogeneous molar genotypes (only 8% diploid biparental; others androgenetic diploid and triploid dispermic) (nguyen2018thegeneticsof pages 1-2).

4.3 Causal genes and example variants (human evidence)

  • NLRP7 (maternal-effect gene; HYDM1, OMIM#231090): A 2023 case series reported homozygous pathogenic variants c.2471+1G>A (splice-site) and c.2571dupC (p.Ile858HisfsTer11) (frameshift); all three NLRP7-positive recurrent HM cases developed GTN and required single-agent chemotherapy with normalization of β-hCG (kocabey2023highriskof pages 2-4, kocabey2023highriskof pages 1-2).
  • KHDC3L (maternal-effect gene; HYDM2, OMIM#614293): review-level evidence indicates a smaller fraction of familial recurrent cases (e.g., ~10–14% in some reviews) and recommends testing after NLRP7 if negative; specific c./p. variants were not present in the extracted context (nasser2024molecularbasisof pages 5-6, kocabey2023highriskof pages 1-2).
  • PADI6: a 2023 narrative review describes recessive PADI6 variants linked to infertility, early embryonic arrest after ART, and HM; specific variants were not provided in the retrieved excerpt (florea2023hydatidiformmole—betweenchromosomal pages 8-9).

4.4 Epigenetic / imprinting abnormalities

A 2024 systematic review summarizes that maternal-effect mutations (particularly NLRP7) are associated with absence of maternal methylation and broader placenta-specific imprinting defects; abnormalities in methylation-related markers (including LINE-1 methylation) have been investigated as predictors of post-molar GTN (nasser2024molecularbasisof pages 15-16, nasser2024molecularbasisof pages 5-6).

5. Environmental Information

Environmental toxin, lifestyle, or infectious-agent causes were not established in the retrieved evidence corpus for HM.

6. Mechanism / Pathophysiology

6.1 Causal chain (high-level)

  1. Abnormal fertilization (empty ovum fertilization → androgenetic diploidy; dispermy → diandric triploidy) or maternal-effect gene dysfunction (biparental but imprinting-defective conceptus). (gonzalez2024gestationaltrophoblasticdisease pages 1-2, nguyen2018thegeneticsof pages 1-2)
  2. Aberrant trophoblast proliferation + villous hydrops → uterine enlargement, bleeding, hyperemesis. (gonzalez2024gestationaltrophoblasticdisease pages 2-4, senat2024gestationaltrophoblasticdisease pages 4-7)
  3. Excess β-hCG secretion → measurable biomarker used for monitoring; may cause thyrotoxicosis via TSH receptor cross-reactivity/mimicry. (gonzalez2024gestationaltrophoblasticdisease pages 2-4)
  4. Persistence after evacuation in a subset → post-molar GTN, diagnosed by FIGO hCG criteria (plateau, rise, or persistent detectable levels) (larsson2025treatmentoutcomesand pages 1-2, senat2024gestationaltrophoblasticdisease pages 4-7).

6.2 Suggested GO/CL terms (examples)

GO Biological Process (examples): trophoblast differentiation, placental development, DNA methylation, genomic imprinting.

CL cell types (examples): cytotrophoblast, syncytiotrophoblast, villous stromal cell.

(IDs not provided in the retrieved sources; should be assigned in curation.)

7. Anatomical Structures Affected

  • Primary: uterus and placental chorionic villi (villous trophoblast), with ovarian involvement via theca lutein cysts (senat2024gestationaltrophoblasticdisease pages 4-7, joyce2024evaluationofbiomarkers pages 62-66).
  • Secondary/complications: metastasis for invasive mole/GTN can involve lungs and vagina (senat2024gestationaltrophoblasticdisease pages 4-7).

Suggested UBERON (examples): uterus, placenta, ovary, lung.

8. Temporal Development

  • Onset: typically detected in early pregnancy / first trimester, with ultrasound diagnosis often feasible around 8–10 weeks in some settings (senat2024gestationaltrophoblasticdisease pages 4-7).
  • Progression: after evacuation, a minority develops persistent disease/post-molar GTN; surveillance relies on β-hCG dynamics over weeks to months, and FIGO criteria define plateau/rise/persistence (larsson2025treatmentoutcomesand pages 1-2, senat2024gestationaltrophoblasticdisease pages 4-7).

9. Inheritance and Population

9.1 Epidemiology (incidence)

Incidence varies geographically: - ~0.57–1.1 per 1,000 pregnancies in Europe/North America/Oceania and ~2 per 1,000 in Japan/Southeast Asia (senat2024gestationaltrophoblasticdisease pages 4-7). - Other sources cite 1–3 per 1,000 in developed regions and up to 10 per 1,000 in some developing settings; Japan 1.02–2.70 per 1,000 live births (zhu2025demographicsriskfactors pages 1-2).

9.2 Post-molar GTN risk (by mole type)

  • CHM: commonly ~15–20% progression risk (florea2023hydatidiformmole—betweenchromosomal pages 9-11, joyce2024evaluationofbiomarkers pages 62-66).
  • PHM: commonly ~0.5–1% (florea2023hydatidiformmole—betweenchromosomal pages 9-11, joyce2024evaluationofbiomarkers pages 62-66). Broader ranges are reported in some summaries (e.g., 7–30% vs 2.5–7.5%) (senat2024gestationaltrophoblasticdisease pages 4-7).

9.3 Inheritance (recurrent/familial forms)

Familial recurrent HM is typically autosomal recessive due to maternal-effect genes such as NLRP7 and KHDC3L (nasser2024molecularbasisof pages 5-6, kocabey2023highriskof pages 1-2).

10. Diagnostics

10.1 Clinical and laboratory tests

  • β-hCG is the key biomarker for diagnosis/surveillance; CHM often shows very high hCG (>100,000 U/L) (joyce2024evaluationofbiomarkers pages 62-66).

10.2 Imaging

  • Transvaginal ultrasound: “snowstorm/blizzard” and cystic/grape-like patterns are classic descriptors (senat2024gestationaltrophoblasticdisease pages 4-7, gonzalez2024gestationaltrophoblasticdisease pages 2-4, riccio2023recurrenthydatidiformmoles pages 1-2).

10.3 Pathology (histopathology) and immunohistochemistry

  • One source explicitly states: “Histopathological examination… remain[s] the gold standard for the diagnosis of molar pregnancy.” (joyce2024evaluationofbiomarkers pages 62-66)
  • p57 (CDKN1C) immunohistochemistry: CHM typically shows loss/absence of p57, whereas PHM retains p57 expression (gonzalez2024gestationaltrophoblasticdisease pages 2-4, joyce2024evaluationofbiomarkers pages 62-66).

10.4 Molecular diagnosis and “gold standard” statements

  • STR genotyping is explicitly called “the gold standard for making the correct diagnosis” in a 2024 GTD review (senat2024gestationaltrophoblasticdisease pages 4-7).
  • STR genotyping is also described as an ancillary method to establish paternal allele patterns supporting CHM (florea2023hydatidiformmole—betweenchromosomal pages 2-4).

10.5 Post-molar GTN diagnostic criteria (FIGO hCG criteria)

FIGO criteria are summarized in multiple sources, including: - hCG plateau (four measurements over ≥3 weeks) and hCG rise (three weekly measurements over ≥2 weeks), or histologic choriocarcinoma (larsson2025treatmentoutcomesand pages 1-2, senat2024gestationaltrophoblasticdisease pages 4-7).

10.6 Differential diagnosis (selected)

  • Hydropic abortus and other “molar mimics” are emphasized as key differentials; morphology alone can be insufficient, with one review stating ~50% of partial moles may not be diagnosed by routine histology (florea2023hydatidiformmole—betweenchromosomal pages 2-4).

11. Outcome / Prognosis

11.1 Remission/cure

Gestational trophoblastic neoplasia (GTN) has very high cure rates with modern management: - A 2024 source states “GTN is the most curative of all gynaecological malignancies with cure rates approaching 100% even in the presence of metastatic disease.” (joyce2024evaluationofbiomarkers pages 62-66) - A Swedish population-based cohort of 185 GTN patients reported primary complete remission 98.4% and relapse 3.2% (larsson2025treatmentoutcomesand pages 1-2). - A 2025 Shanghai cohort of 506 HM patients found 8.3% progressed to post-molar GTN and all achieved complete response after treatment (zhu2025demographicsriskfactors pages 1-2).

11.2 Prognostic factors for progression

Risk factors for post-molar GTN include very high hCG (>100,000 mIU/mL), uterine size larger than expected, large theca lutein cysts, and older maternal age (florea2023hydatidiformmole—betweenchromosomal pages 9-11, zhu2025demographicsriskfactors pages 1-2).

12. Treatment

12.1 Standard treatment for hydatidiform mole (fertility-preserving)

  • Ultrasound-guided uterine evacuation (suction dilation & curettage / D&C) is standard for patients wishing to preserve fertility (gonzalez2024gestationaltrophoblasticdisease pages 4-5, riccio2023recurrenthydatidiformmoles pages 1-2).

12.2 Post-evacuation surveillance

  • β-hCG monitoring: every 1–2 weeks until normalization; after normalization, monthly for 6 months for CHM; for PHM, one additional monthly normal measurement is recommended (gonzalez2024gestationaltrophoblasticdisease pages 2-4, gonzalez2024gestationaltrophoblasticdisease pages 4-5).

12.3 Hysterectomy

  • For those not desiring future fertility, hysterectomy with salpingectomy is recommended in one review and may reduce subsequent GTN risk by ~80% (gonzalez2024gestationaltrophoblasticdisease pages 4-5).
  • In low-risk GTN, therapeutic hysterectomy shortened time to hCG normalization (48 vs 74 days) in a population-based cohort (larsson2025treatmentoutcomesand pages 1-2).

12.4 Chemotherapy (for GTN)

  • Management of GTN includes chemotherapy guided by risk stratification systems (FIGO/WHO) (larsson2025treatmentoutcomesand pages 1-2, senat2024gestationaltrophoblasticdisease pages 4-7).
  • In recurrent HM with NLRP7 pathogenic variants, low-risk GTN was treated with single-agent methotrexate, with subsequent β-hCG normalization (kocabey2023highriskof pages 2-4).

Suggested MAXO terms (examples): uterine evacuation (suction curettage), hysterectomy, chemotherapy (methotrexate-based), serial hCG monitoring.

13. Prevention

No vaccine or primary prevention strategies were established in the retrieved evidence corpus. Secondary prevention relies on timely diagnosis, complete evacuation, and structured hCG surveillance to detect post-molar GTN early (gonzalez2024gestationaltrophoblasticdisease pages 2-4, senat2024gestationaltrophoblasticdisease pages 4-7).

14. Other Species / Natural Disease

Not addressed in the retrieved evidence corpus.

15. Model Organisms

Not addressed in the retrieved evidence corpus.

Recent developments & “latest research” highlights (2023–2025 evidence in this corpus)

  1. Precision diagnosis emphasis: STR genotyping explicitly described as the diagnostic “gold standard” in a 2024 review (senat2024gestationaltrophoblasticdisease pages 4-7), reflecting ongoing movement toward genetically anchored diagnosis.
  2. Expanded IHC adjunct panels: Beyond p57, an IHC study tested imprinted genes and found RB1 and TSSC3 positive in 100% PHM/non-molar cases but only in a minority of CHM, supporting their adjunctive role when molecular testing is limited (chia2023diagnosticutilityof pages 1-2).
  3. Risk prediction modeling (real-world implementation): A 2019–2023 Shanghai cohort (n=506) developed and evaluated multivariable predictors of post-molar GTN incorporating age, β-hCG ratio, and ultrasound characteristics, and also reported reproductive outcomes after HM (zhu2025demographicsriskfactors pages 1-2).

Embedded summary tables (for knowledge base curation)

Concept Details Source
Disease name Hydatidiform mole (HM); a gestational trophoblastic disease classified into complete hydatidiform mole (CHM) and partial hydatidiform mole (PHM) (senat2024gestationaltrophoblasticdisease pages 4-7, gonzalez2024gestationaltrophoblasticdisease pages 2-4, joyce2024evaluationofbiomarkers pages 62-66)
Common synonyms / related terms Molar pregnancy; complete mole; partial mole; HM/CHM/PHM; post-molar gestational trophoblastic neoplasia (GTN) refers to neoplastic progression after HM (senat2024gestationaltrophoblasticdisease pages 4-7, larsson2025treatmentoutcomesand pages 1-2, joyce2024evaluationofbiomarkers pages 62-66)
Classification framework Genetic classification distinguishes CHM (paternal-only genome) from PHM (triploid conceptus with maternal + paternal contribution); FIGO hCG criteria are used for post-molar GTN diagnosis/risk assessment (senat2024gestationaltrophoblasticdisease pages 4-7, larsson2025treatmentoutcomesand pages 1-2, gonzalez2024gestationaltrophoblasticdisease pages 2-4)
ICD / diagnostic codes ICD-10 code explicitly reported: non-specified hydatidiform mole O01.9; additional GTN-related codes reported include invasive mole D39.2A, PSTT D39.2C, choriocarcinoma C58.9, ETT morphology codes 91043/91053/m91053 (larsson2025treatmentoutcomesand pages 1-2)
Complete hydatidiform mole (CHM): core genetics Usually diploid, most commonly 46,XX; androgenetic/paternal-only genome; typically arises from fertilization of an empty ovum by one sperm with duplication or by two sperm (senat2024gestationaltrophoblasticdisease pages 4-7, gonzalez2024gestationaltrophoblasticdisease pages 2-4, gonzalez2024gestationaltrophoblasticdisease pages 1-2)
Partial hydatidiform mole (PHM): core genetics Usually triploid, commonly 69,XXY (also 69,XXX/69,XYY reported); diandric triploidy with maternal and paternal contribution, often from dispermy of a normal ovum (senat2024gestationaltrophoblasticdisease pages 4-7, gonzalez2024gestationaltrophoblasticdisease pages 2-4, gonzalez2024gestationaltrophoblasticdisease pages 1-2)
p57 immunostaining pattern in CHM Loss/absence of nuclear p57 expression in villous cytotrophoblast and stromal cells is characteristic of CHM because maternal genome contribution is absent (gonzalez2024gestationaltrophoblasticdisease pages 1-2, joyce2024evaluationofbiomarkers pages 62-66, gonzalez2024gestationaltrophoblasticdisease pages 2-4)
p57 immunostaining pattern in PHM Retained/intact nuclear p57 expression is expected in PHM because maternal genome contribution is present (gonzalez2024gestationaltrophoblasticdisease pages 1-2, joyce2024evaluationofbiomarkers pages 62-66, gonzalez2024gestationaltrophoblasticdisease pages 2-4)
Diagnostic gold standard / definitive diagnosis STR genotyping is explicitly described as the gold standard for correct diagnosis in one 2024 review; another review states definitive diagnosis is made by histopathologic examination, with p57 and molecular testing used as ancillary/complementary tools (senat2024gestationaltrophoblasticdisease pages 4-7, gonzalez2024gestationaltrophoblasticdisease pages 2-4)
GTN progression risk after CHM Reported progression risk to GTN is about 15–20%; some reviews cite broader ranges up to 7–30% or note post-CHM GTN risk as high as 25% in a study (florea2023hydatidiformmole—betweenchromosomal pages 9-11, senat2024gestationaltrophoblasticdisease pages 4-7, gonzalez2024gestationaltrophoblasticdisease pages 2-4, joyce2024evaluationofbiomarkers pages 62-66)
GTN progression risk after PHM Reported progression risk to GTN is about 0.5–1%; some reviews cite broader ranges up to 2.5–7.5% (florea2023hydatidiformmole—betweenchromosomal pages 9-11, senat2024gestationaltrophoblasticdisease pages 4-7, joyce2024evaluationofbiomarkers pages 62-66)
hCG follow-up after evacuation Serum beta-hCG should be monitored every 1–2 weeks until normal; after normalization, monthly monitoring for 6 months is recommended for CHM, while PHM requires one additional monthly normal measurement (gonzalez2024gestationaltrophoblasticdisease pages 2-4)
Epidemiology snapshot Incidence reported at ~0.57–1.1 per 1,000 pregnancies in Europe/North America/Oceania and ~2 per 1,000 in Japan/Southeast Asia; other review data cite 1–2 per 1,000 in Europe/North America and up to 10 per 1,000 in India/Indonesia (senat2024gestationaltrophoblasticdisease pages 4-7, joyce2024evaluationofbiomarkers pages 62-66)
Prognosis / cure context GTN is highly curable with modern management; overall cure rates are reported as exceeding 90%, and one review states cure rates approach 100% even with metastatic disease (larsson2025treatmentoutcomesand pages 1-2, joyce2024evaluationofbiomarkers pages 62-66)

Table: This table summarizes key terminology, diagnostic coding, and the most clinically important distinctions between complete and partial hydatidiform mole, including genetics, p57 staining, and GTN progression risk. It is useful as a compact reference for disease knowledge base curation and differential diagnosis.

Category Gene / marker Inheritance / origin Molecular mechanism Example pathogenic variants / pattern Key clinical notes Evidence
Maternal-effect gene NLRP7 Typically autosomal recessive in familial recurrent hydatidiform mole (FRHM); affected conceptions are often diploid biparental Oocyte maternal-effect gene; defective establishment/maintenance of maternal imprinting with placenta-specific methylation defects; reported associations with altered DNMT3A, LIN28B, ERVWE1, LINE-1, and STAT5A methylation/expression c.2471+1G>A (canonical splice-site; homozygous), c.2571dupC, p.Ile858HisfsTer11 (frameshift; homozygous), c.2810+2T>G (splice-site); broader series show multiple homozygous or compound-heterozygous truncating/splice variants Major cause of FRHM; reported in ~40–80% of FRHM/RHM cohorts. In a 113-patient series, all moles from patients with NLRP7/KHDC3L variants were diploid biparental. In a 3-case 2023 series, all NLRP7-positive recurrent cases progressed to GTN after evacuation and required single-agent methotrexate; one review notes only ~7% chance of normal live birth with biallelic NLRP7 variants, supporting counseling about oocyte donation (kocabey2023highriskof pages 2-4, nasser2024molecularbasisof pages 5-6, florea2023hydatidiformmole—betweenchromosomal pages 8-9, kocabey2023highriskof pages 1-2, nguyen2018thegeneticsof pages 1-2)
Maternal-effect gene KHDC3L Typically autosomal recessive; affected conceptions classically diploid biparental Maternal-effect / imprinting gene involved in oocyte competence; variants associated with abnormal genomic imprinting and recurrent biparental mole formation No variant examples with c./p. notation were provided in the available context; review-level evidence cites protein-truncating mutations and p.M1V founder mutation Accounts for roughly 5–14% of familial recurrent mole cases depending on cohort/review; testing is generally recommended after NLRP7 if NLRP7 is negative in recurrent HM workup (nasser2024molecularbasisof pages 15-16, nasser2024molecularbasisof pages 5-6, florea2023hydatidiformmole—betweenchromosomal pages 8-9, kocabey2023highriskof pages 1-2, nguyen2018thegeneticsof pages 1-2)
Maternal-effect gene PADI6 Recessive maternal-effect etiology reported in recurrent HM / reproductive failure SCMC-related maternal-effect dysfunction; linked to abnormal early embryogenesis and HM, with review evidence that missense variants may be milder than protein-truncating variants; contributes to imprinting/early developmental failure rather than classic sporadic androgenetic mole biology Specific c./p. examples were not available in the provided context Linked to primary female infertility, early embryonic arrest after ART, and hydatidiform mole; should be considered in recurrent/biparental mole differential when NLRP7/KHDC3L testing is unrevealing (nasser2024molecularbasisof pages 15-16, florea2023hydatidiformmole—betweenchromosomal pages 8-9)
Genotype class Diploid biparental HM Maternal-effect gene-associated recurrent form Presence of both maternal and paternal genomes despite complete-mole phenotype; reflects imprinting failure rather than androgenetic conception Genotype pattern: diploid biparental Strongly enriched in women with NLRP7/KHDC3L variants; in the 113-patient study, tissues from mutation-positive patients were all diploid biparental, whereas mutation-negative recurrent cases were heterogeneous (nasser2024molecularbasisof pages 5-6, nguyen2018thegeneticsof pages 1-2)
Genotype class Diploid androgenetic HM Usually sporadic, non-maternal-effect form Paternal-only genome, classic complete mole mechanism Genotype pattern: diploid androgenetic monospermic Seen commonly among mutation-negative recurrent/sporadic cases; generally distinct from biparental recurrent mole syndrome (nguyen2018thegeneticsof pages 1-2)
Genotype class Triploid dispermic HM Usually sporadic partial mole biology Diandric triploidy from dispermy; not the classic maternal-effect recurrent biparental mechanism Genotype pattern: triploid dispermic In mutation-negative recurrent cases, a substantial fraction of tissues were triploid dispermic; these patients tended to have fewer reproductive losses and more live births than mutation-positive patients (florea2023hydatidiformmole—betweenchromosomal pages 8-9, nguyen2018thegeneticsof pages 1-2)
Diagnostic marker RB1 IHC adjunct marker; not a causal gene here Paternally imprinted/maternally expressed pattern useful for distinguishing CHM from PHM/non-molar abortus when p57 is equivocal Positive in 100% of PHM and non-molar abortuses; positive in only 10.3% of CHM Useful adjunct to p57 in laboratories lacking molecular testing or in equivocal cases (chia2023diagnosticutilityof pages 1-2)
Diagnostic marker TSSC3 IHC adjunct marker; not a causal gene here Paternally imprinted/maternally expressed pattern useful for distinguishing CHM from PHM/non-molar abortus Positive in 100% of PHM and non-molar abortuses; positive in only 31% of CHM Useful adjunct to p57 for CHM vs PHM/non-molar distinction, especially where molecular genotyping is unavailable (chia2023diagnosticutilityof pages 1-2)
Diagnostic marker DOG1 IHC adjunct evaluated in study Tested as a possible adjunct marker Uniformly negative in all cell types/case groups in the cited study Not useful diagnostically in this setting based on available evidence (chia2023diagnosticutilityof pages 1-2)
Diagnostic marker DNMT1 / GATA3 IHC adjuncts evaluated in study Maternally imprinted marker expression assessed across villous/trophoblastic compartments Expressed in all cases except one CHM with negative GATA3 Less discriminatory than RB1/TSSC3 for routine CHM vs PHM separation in the cited cohort (chia2023diagnosticutilityof pages 1-2)

Table: This table summarizes the main maternal-effect genes and genotype classes implicated in hydatidiform mole, especially recurrent biparental forms, and adds key diagnostic immunohistochemical adjuncts beyond p57. It is useful for linking molecular etiology to recurrence risk, imprinting defects, and practical pathology workflows.

Visual evidence (diagnostic table)

A key diagnostic comparison table (CHM vs PHM) was retrieved as cropped images from Gonzalez et al. 2024 (gonzalez2024gestationaltrophoblasticdisease media 25fa70d0, gonzalez2024gestationaltrophoblasticdisease media e5bff0f9).

Evidence type notes

  • Human clinical evidence: cohort outcomes, progression risk estimates, imaging/lab surveillance, and remission/relapse outcomes (larsson2025treatmentoutcomesand pages 1-2, zhu2025demographicsriskfactors pages 1-2, joyce2024evaluationofbiomarkers pages 62-66).
  • Human pathology/molecular diagnostics evidence: p57 patterns, STR genotyping as gold standard, and adjunct IHC markers (senat2024gestationaltrophoblasticdisease pages 4-7, joyce2024evaluationofbiomarkers pages 62-66, chia2023diagnosticutilityof pages 1-2).
  • Human genetic case-series evidence: NLRP7 variant examples and associated GTN progression in recurrent HM (kocabey2023highriskof pages 2-4, kocabey2023highriskof pages 1-2).

Direct quotes from abstracts (available in evidence)

  • NLRP7/embryogenesis mechanism abstract quote: “NLRP7 dysfunctions affect embryonic development and lead to Hydatidiform Moles…” (nasser2024molecularbasisof pages 5-6)

(Additional abstract-quote extraction was limited by the specific full-text segments retrieved in this run; primary claims are otherwise evidence-cited above.)

References

  1. (joyce2024evaluationofbiomarkers pages 62-66): CM Joyce. Evaluation of biomarkers for the diagnosis, management and. Unknown journal, 2024.

  2. (senat2024gestationaltrophoblasticdisease pages 4-7): Hanna Senat, Patrycja Grabowska, Aleksandra Senat, Patrycja Bolla, Aleksandra Madej, and Zuzanna Marczyńska. Gestational trophoblastic disease a contemporary review of diagnostic and pathology. current challenge and future directions for gynecologists and obstetricians. Journal of Education, Health and Sport, 59:73-86, Feb 2024. URL: https://doi.org/10.12775/jehs.2024.59.005, doi:10.12775/jehs.2024.59.005. This article has 1 citations.

  3. (gonzalez2024gestationaltrophoblasticdisease pages 2-4): Jeffrey Gonzalez, Meagan Popp, Stephanie Ocejo, Alvaro Abreu, Hisham F. Bahmad, and Robert Poppiti. Gestational trophoblastic disease: complete versus partial hydatidiform moles. Diseases, 12:159, Jul 2024. URL: https://doi.org/10.3390/diseases12070159, doi:10.3390/diseases12070159. This article has 23 citations.

  4. (gonzalez2024gestationaltrophoblasticdisease pages 1-2): Jeffrey Gonzalez, Meagan Popp, Stephanie Ocejo, Alvaro Abreu, Hisham F. Bahmad, and Robert Poppiti. Gestational trophoblastic disease: complete versus partial hydatidiform moles. Diseases, 12:159, Jul 2024. URL: https://doi.org/10.3390/diseases12070159, doi:10.3390/diseases12070159. This article has 23 citations.

  5. (larsson2025treatmentoutcomesand pages 1-2): Agnes Larsson, Emelie Wallin, Mats Nilsson, and Ulrika Joneborg. Treatment outcomes and the role of surgery in gestational trophoblastic neoplasia: a population-based cohort study. Acta Oncologica, 64:807-814, Jun 2025. URL: https://doi.org/10.2340/1651-226x.2025.43274, doi:10.2340/1651-226x.2025.43274. This article has 1 citations and is from a peer-reviewed journal.

  6. (kocabey2023highriskof pages 1-2): M. Kocabey, I. Gulhan, A. Koc, T. Cankaya, V. Karatasli, and A. Ileri. High risk of gestational trophoblastic neoplasia development in recurrent hydatidiform moles with nlrp7 pathogenic variations. Balkan Journal of Medical Genetics : BJMG, 25:45-50, Dec 2023. URL: https://doi.org/10.2478/bjmg-2022-0025, doi:10.2478/bjmg-2022-0025. This article has 5 citations.

  7. (zhu2025demographicsriskfactors pages 1-2): Tingting Zhu, Guohua Zhu, Jiahui Ma, Xiaojuan Yu, Tingting Chen, Xiang Tao, Li Sun, Xin Lu, and Yan Du. Demographics, risk factors associated with malignant progression, and pregnancy outcomes of hydatidiform mole: a retrospective cohort study in shanghai, china. Frontiers in Oncology, Jul 2025. URL: https://doi.org/10.3389/fonc.2025.1643590, doi:10.3389/fonc.2025.1643590. This article has 1 citations.

  8. (florea2023hydatidiformmole—betweenchromosomal pages 8-9): Andreea Florea, Lavinia Caba, Ana-Maria Grigore, Lucian-Mihai Antoci, Mihaela Grigore, Mihaela I. Gramescu, and Eusebiu Vlad Gorduza. Hydatidiform mole—between chromosomal abnormality, uniparental disomy and monogenic variants: a narrative review. Life, 13:2314, Dec 2023. URL: https://doi.org/10.3390/life13122314, doi:10.3390/life13122314. This article has 13 citations.

  9. (florea2023hydatidiformmole—betweenchromosomal pages 9-11): Andreea Florea, Lavinia Caba, Ana-Maria Grigore, Lucian-Mihai Antoci, Mihaela Grigore, Mihaela I. Gramescu, and Eusebiu Vlad Gorduza. Hydatidiform mole—between chromosomal abnormality, uniparental disomy and monogenic variants: a narrative review. Life, 13:2314, Dec 2023. URL: https://doi.org/10.3390/life13122314, doi:10.3390/life13122314. This article has 13 citations.

  10. (riccio2023recurrenthydatidiformmoles pages 1-2): S. Riccio, F. Galanti, M. Scudo, L. Di Troia, M. G. Ferrillo, F. Manzara, P. Ianiri, and F. A. Battaglia. Recurrent hydatidiform moles: a clinical challenge—a case report and an update on management and therapeutical strategies. Case Reports in Obstetrics and Gynecology, 2023:1-5, Jun 2023. URL: https://doi.org/10.1155/2023/3752274, doi:10.1155/2023/3752274. This article has 4 citations.

  11. (nguyen2018thegeneticsof pages 1-2): Ngoc Minh Phuong Nguyen, Yassemine Khawajkie, Nawel Mechtouf, Maryam Rezaei, Magali Breguet, Elvira Kurvinen, Sujatha Jagadeesh, Asli Ece Solmaz, Monica Aguinaga, Reda Hemida, Mehmet Ibrahim Harma, Cécile Rittore, Kurosh Rahimi, Jocelyne Arseneau, Karine Hovanes, Ronald Clisham, Tiffanee Lenzi, Bonnie Scurry, Marie-Claude Addor, Rashmi Bagga, Genevieve Girardet Nendaz, Vildana Finci, Gemma Poke, Leslie Grimes, Nerine Gregersen, Kayla York, Pierre-Adrien Bolze, Chirag Patel, Hossein Mozdarani, Jacques Puechberty, Jessica Scotchie, Majid Fardaei, Muge Harma, R. J. McKinlay Gardner, Trilochan Sahoo, Tracy Dudding-Byth, Radhika Srinivasan, Philippe Sauthier, and Rima Slim. The genetics of recurrent hydatidiform moles: new insights and lessons from a comprehensive analysis of 113 patients. Modern Pathology, 31:1116-1130, Jul 2018. URL: https://doi.org/10.1038/s41379-018-0031-9, doi:10.1038/s41379-018-0031-9. This article has 93 citations and is from a domain leading peer-reviewed journal.

  12. (kocabey2023highriskof pages 2-4): M. Kocabey, I. Gulhan, A. Koc, T. Cankaya, V. Karatasli, and A. Ileri. High risk of gestational trophoblastic neoplasia development in recurrent hydatidiform moles with nlrp7 pathogenic variations. Balkan Journal of Medical Genetics : BJMG, 25:45-50, Dec 2023. URL: https://doi.org/10.2478/bjmg-2022-0025, doi:10.2478/bjmg-2022-0025. This article has 5 citations.

  13. (nasser2024molecularbasisof pages 5-6): Shadha Nasser, Mohammed Bahutair, R. Dube, Manjunatha Goud, Bellary Kuruba, Rasha Khougali Abdelrahman Aziz, Attia Salama, Mohamed Anas, Mohamed Anas Mohamed Faruk Patni, Subhranshu Sekhar Kar, and Rakhee Kar. Molecular basis of hydatidiform moles—a systematic review. International Journal of Molecular Sciences, 25:8739, Aug 2024. URL: https://doi.org/10.3390/ijms25168739, doi:10.3390/ijms25168739. This article has 10 citations.

  14. (nasser2024molecularbasisof pages 15-16): Shadha Nasser, Mohammed Bahutair, R. Dube, Manjunatha Goud, Bellary Kuruba, Rasha Khougali Abdelrahman Aziz, Attia Salama, Mohamed Anas, Mohamed Anas Mohamed Faruk Patni, Subhranshu Sekhar Kar, and Rakhee Kar. Molecular basis of hydatidiform moles—a systematic review. International Journal of Molecular Sciences, 25:8739, Aug 2024. URL: https://doi.org/10.3390/ijms25168739, doi:10.3390/ijms25168739. This article has 10 citations.

  15. (florea2023hydatidiformmole—betweenchromosomal pages 2-4): Andreea Florea, Lavinia Caba, Ana-Maria Grigore, Lucian-Mihai Antoci, Mihaela Grigore, Mihaela I. Gramescu, and Eusebiu Vlad Gorduza. Hydatidiform mole—between chromosomal abnormality, uniparental disomy and monogenic variants: a narrative review. Life, 13:2314, Dec 2023. URL: https://doi.org/10.3390/life13122314, doi:10.3390/life13122314. This article has 13 citations.

  16. (gonzalez2024gestationaltrophoblasticdisease pages 4-5): Jeffrey Gonzalez, Meagan Popp, Stephanie Ocejo, Alvaro Abreu, Hisham F. Bahmad, and Robert Poppiti. Gestational trophoblastic disease: complete versus partial hydatidiform moles. Diseases, 12:159, Jul 2024. URL: https://doi.org/10.3390/diseases12070159, doi:10.3390/diseases12070159. This article has 23 citations.

  17. (chia2023diagnosticutilityof pages 1-2): Wai Kit Chia, Pik Yuen Chia, Nor Haslinda Abdul Aziz, Salwati Shuib, Muaatamarulain Mustangin, Yoke Kqueen Cheah, Teck Yee Khong, Yin Ping Wong, and Geok Chin Tan. Diagnostic utility of tssc3 and rb1 immunohistochemistry in hydatidiform mole. International Journal of Molecular Sciences, 24:9656, Jun 2023. URL: https://doi.org/10.3390/ijms24119656, doi:10.3390/ijms24119656. This article has 6 citations.

  18. (gonzalez2024gestationaltrophoblasticdisease media 25fa70d0): Jeffrey Gonzalez, Meagan Popp, Stephanie Ocejo, Alvaro Abreu, Hisham F. Bahmad, and Robert Poppiti. Gestational trophoblastic disease: complete versus partial hydatidiform moles. Diseases, 12:159, Jul 2024. URL: https://doi.org/10.3390/diseases12070159, doi:10.3390/diseases12070159. This article has 23 citations.

  19. (gonzalez2024gestationaltrophoblasticdisease media e5bff0f9): Jeffrey Gonzalez, Meagan Popp, Stephanie Ocejo, Alvaro Abreu, Hisham F. Bahmad, and Robert Poppiti. Gestational trophoblastic disease: complete versus partial hydatidiform moles. Diseases, 12:159, Jul 2024. URL: https://doi.org/10.3390/diseases12070159, doi:10.3390/diseases12070159. This article has 23 citations.

Artifacts